A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Keros Therapeutics (KROS) to $41 from $44 and keeps an Outperform rating on ...

After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

While high blood pressure can contribute to renovascular disease, having renal (kidney) problems can also increase blood ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey. Professional guidelines say that when pulmonary ...

A new treatment, Sotatercept, for pulmonary arterial hypertension (PAH) has recently been approved by the MHRA ...

coronary artery disease, diabetes, heart failure, hypercholesterolemia, hypertension, obesity, and smoking history. TRIUMPH assessed improvement in exercise capacity as measured by the 6-minute ...